Graziano Robert F.,Gupta Ashok K.,Kim Su Young,Wigginton Jon
申请号：
NZ63140513
公开号：
NZ631405A
申请日:
2013.10.02
申请国别(地区):
NZ
年份:
2017
代理人:
摘要：
Disclosed is a combination of: (a) an anti-PD-1 antibody comprising the CDR1, CDR2 and CDR3 domains in a heavy chain variable region having the sequence set forth in SEQ ID NO:19, and the CDR1, CDR2 and CDR3 domains in a light chain variable region having the sequence set forth in SEQ ID NO:21； and (b) an anti-KIR antibody comprising the CDR1, CDR2 and CDR3 domains in a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and the CDR1, CDR2 and CDR3 domains in a light chain variable region having the sequence set forth in SEQ ID NO:5； wherein the anti-PD-1 antibody and the anti-KIR antibody are formulated for co-administration to a patient afflicted with cancer in at least one cycle, wherein the dosing schedule for co-administration to the patient includes two doses of the anti-KIR antibody at a dose of 0.1, 0.3, 1, 3, 6, or 10 mg/kg, and four doses of the anti-PD-1 antibody at a dose of 3 mg/kg.
